726 reports of this reaction
4.5% of all ENCORAFENIB reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for ENCORAFENIB, manufactured by Array BioPharma Inc.. There are 726 FDA adverse event reports linking ENCORAFENIB to FATIGUE. This represents approximately 4.5% of all 16,241 adverse event reports for this drug.
Patients taking ENCORAFENIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ENCORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ENCORAFENIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 726 FDA reports for ENCORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.5% of all adverse event reports for ENCORAFENIB, making it a notable side effect.
If you experience fatigue while taking ENCORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.